Evidence map›Paper›PMID 34671130›Full record

ArticleBritish journal of cancer2022

Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.

Kristine Aasebø, Jarle Bruun, Christian H Bergsland, Luís Nunes, Geir Egil Eide, Per Pfeiffer, Olav Dahl, Bengt Glimelius, Ragnhild A Lothe, Halfdan Sorbye

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Kristine AasebøDepartment of Clinical Science, University of Bergen, Bergen, Norway. kristine.aasebo@helse-bergen.no.
Jarle BruunDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Christian H BergslandDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-7700-8156
Luís NunesDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0002-3391-1607
Geir Egil EideDepartment of Global Public Health and Primary Care, Lifestyle Epidemiology Group, University of Bergen, Bergen, Norway.
Per PfeifferDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Olav DahlDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Bengt GlimeliusDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Ragnhild A LotheDepartment of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Halfdan SorbyeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOOslo University Hospital · NOUppsala University · SEOdense University Hospital · DKUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumour-infiltrating CD3, CD8 lymphocytes and CD68 macrophages are associated with favourable prognosis in localised colorectal cancer, but the effect in metastatic colorectal cancer (mCRC) is not established.

methodsA Scandinavian population-based cohort of non-resectable mCRC patients was studied. Tissue microarrays (n = 460) were stained with CD3, CD8 and CD68 using fluorescence-based multiplex immunohistochemistry. Associations with clinicopathological variables, overall survival (OS) and progression-free survival were estimated.

resultsTwo-thirds of microsatellite instable (MSI) and one-fourth of microsatellite stable (MSS) tumours displayed the highest quartile density of CD8. For CD3 high vs low cases, median OS was 20 vs 16 months (HR: 0.76, 95% CI: 0.59, 0.76, p = 0.025) with 3-year OS of 27 vs 13%. For CD68 high vs low cases, median OS was 23 vs 15 months (HR: 0.69, 95% CI: 0.54, 0.88, p = 0.003) with 3-year OS of 28 vs 12%. MSI, BRAF mutation and CDX2 loss were negative prognostic markers independent of tumour immune infiltration.

conclusionsIn mCRC, high lymphocyte infiltration was found in proportions of MSI and MSS tumours-potential subgroups of immunotherapy response. Tumour-infiltrating CD3 lymphocytes and CD68 macrophages were associated with median and long-term survival. MSI was a significant negative prognostic marker despite high immunogenicity.

Indexed as

Microsatellite InstabilityAdultAgedAged, 80 and overCDX2 Transcription FactorColorectal NeoplasmsFemaleHumansLymphocytes, Tumor-InfiltratingMacrophagesMaleMiddle AgedNeoplasm MetastasisPrognosisProto-Oncogene Proteins B-rafSurvival RateBRAF protein, humanCDX2 protein, humanCDX2 Transcription FactorProto-Oncogene Proteins B-raf

Identifiers

PMID34671130
PMCPMC8727629
OpenAlexW3206929437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.